Severe hypovitaminosis D correlates with increased inflammatory markers in HIV infected patients

BMC Infectious Diseases

Lionel Piroth¹  Jean-Francis Maillefert⁴  Pascal Chavanet¹  Laurence Duvillard³  Delphine Croisier⁵  Jean-Claude Guilland³  Stephanie Ewing³  Paul Ornetti⁴  Christine Piroth²  Sophie Mahy⁵  Thiphaine Ansemant² 

[1] University of Burgundy, Dijon, F-21079, France;Rheumatology Department, CHU, Dijon, F-21078, France;INSERM U866 and Laboratory of biochemistry, CHU, Dijon, France;INSERM U887, Dijon, F-21079, France;Infectious Diseases Department, CHU, Dijon, 21079, France

关键词: 25-hydroxyvitamin D;    Inflammation;    HIV;    Bone metabolism;    Antiretroviral therapy;   

Others  :  1158613
DOI  :  10.1186/1471-2334-13-7

 received in 2012-05-18, accepted in 2012-12-14,  发布年份 2013

【 摘 要 】

Background

Even though it has been suggested that antiretroviral therapy has an impact on severe hypovitaminosis D (SHD) in HIV infected patients, it could be speculated that the different levels of residual inflammation on HAART (Highly Active Anti Retroviral Therapy) could contribute to SHD and aggravate bone catabolism in these patients.

Methods

A cross-sectional study was carried out in an unselected cohort of 263 HIV infected outpatients consulting during Spring 2010. Clinical examinations were performed and medical history, food habits, sun exposure and addictions were collected. Fasting blood samples were taken for immunological, virological, inflammation, endocrine and bone markers evaluations.

Results

Ninety-five (36%) patients had SHD. In univariate analysis, a significant and positive association was found between SHD and IL6 (p = 0.001), hsCRP (p = 0.04), increased serum C-Telopeptides X (CTX) (p = 0.005) and Parathyroid Hormon (PTH) (p < 0.0001) levels. In multivariate analysis, SHD deficiency correlated significantly with increased IL-6, high serum CTX levels, lower mean daily exposure to the sun, current or past smoking, hepatitis C, and functional status (falls), but not with the time spent on the current HAART (by specific drug or overall).

Conclusions

SHD is frequent and correlates with inflammation in HIV infected patients. Since SHD is also associated with falls and increased bone catabolism, it may be of interest to take into account not only the type of antiretroviral therapy but also the residual inflammation on HAART in order to assess functional and bone risks. This finding also suggests that vitamin D supplementation may be beneficial in these HIV-infected patients.

【 授权许可】

   
2013 Ansemant et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

【 参考文献 】

• [1]Rodriguez M, Daniels B, Gunawardene S, Robbins GK: High frequency of vitamin D deficiency in ambulatory HIV-Positive patients. AIDS Res Hum Retroviruses 2009, 25:9-14.
• [2]Blanchard P: Masterclass: HIV-infection and osteopathy. Int J Osteop Med 2009, 12:115-120.
• [3]Vescini F, Cozzi-Lepri A, Borderi M, Re MC, Maggiolo F, De Luca A, et al.: Prevalence of hypovitaminosis D and factors associated with vitamin D deficiency and morbidity among HIV-infected patients enrolled in a large Italian cohort. J Acquir Immune Defic Syndr 2011, 58:163-172.
• [4]Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, et al.: Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study. AIDS 2011, 25:1305-1315.
• [5]Bischoff-Ferrari HA, Willett WC, Orav EJ, Lips P, Meunier PJ, Lyons RA, et al.: A pooled analysis of vitamin D dose requirements for fracture prevention. N Engl J Med 2012, 367:40-49.
• [6]Parker J, Hashmi O, Dutton D, Mavrodaris A, Stranges S, Kandala NB, et al.: Levels of vitamin D and cardiometabolic disorders: systematic review and meta-analysis. Maturitas 2010, 65:225-236.
• [7]Overton ET, Yin MT: The rapidly evolving research on vitamin D among HIV-infected populations. Curr Infect Dis Rep 2011, 13:83-93.
• [8]Van Den Bout-Van Den Beukel CJ, Fievez L, Michels M, Sweep FC, Hermus AR, Bosch ME, et al.: Vitamin D deficiency among HIV type 1-infected individuals in the Netherlands: effects of antiretroviral therapy. AIDS Res Hum Retroviruses 2008, 24:1375-1382.
• [9]Libois A, Clumeck N, Kabeya K, Gerard M, De Wit S, Poll B, et al.: Risk factors of osteopenia in HIV-infected women: no role of antiretroviral therapy. Maturitas 2010, 65:51-54.
• [10]Piso RJ, Rothen M, Rothen JP, Stahl M: Markers of bone turnover are elevated in patients with antiretroviral treatment independent of the substance used. J Acquir Immune Defic Syndr 2011, 56:320-324.
• [11]McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al.: Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: aids clinical trials group A5224s, a substudy of ACTG A5202. J Infect Dis 2011, 203:1791-1801.
• [12]Lau B, Sharrett AR, Kingsley LA, Post W, Palella FJ, Visscher B, Gange SJ: C-reactive protein is a marker for human immunodeficiency virus disease progression. Arch Intern Med 2006, 166:64-70.
• [13]Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al.: Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008, 5:e203.
• [14]Fardellone P, Sebert JL, Bouraya M, Bonidan O, Leclercq G, Doutrellot C, et al.: [Evaluation of the calcium content of diet by frequential self-questionnaire]. Rev Rhum Mal Osteoartic 1991, 58:99-103.
• [15]Mueller NJ, Fux CA, Ledergerber B, Elzi L, Schmid P, Dang T, et al.: High prevalence of severe vitamin D deficiency in combined antiretroviral therapy-naive and successfully treated Swiss HIV patients. AIDS 2010, 24:1127-1134.
• [16]Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, et al.: HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS 2009, 23:929-939.
• [17]Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al.: Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis 2011, 52:396-405.
• [18]Bucharles S, Barberato SH, Stinghen AE, Gruber B, Meister H, Mehl A, et al.: Hypovitaminosis D is associated with systemic inflammation and concentric myocardial geometric pattern in hemodialysis patients with low iPTH levels. Nephron Clin Pract 2011, 118:c384-c391.
• [19]Bellia A, Garcovich C, D'Adamo M, Lombardo M, Tesauro M, Donadel G, et al.: Serum 25-hydroxyvitamin D levels are inversely associated with systemic inflammation in severe obese subjects. Intern Emerg Med 2011. Epub ahead of print
• [20]Guillot X, Semerano L, Saidenberg-Kermanac’h N, Falgarone G, Boissier MC: Vitamin D and inflammation. Joint Bone Spine 2010, 77:552-557.
• [21]Bischoff-Ferrari HA, Dawson-Hughes B, Willett WC, Staehelin HB, Bazemore MG, Zee RY, Wong JB: Effect of Vitamin D on falls: a meta-analysis. JAMA 2004, 291:1999-2006.
• [22]George J, Ganesh HK, Acharya S, Bandgar TR, Shivane V, Karvat A, et al.: Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol 2009, 15:3516-3522.
• [23]Wasserman P, Rubin DS: Highly prevalent vitamin D deficiency and insufficiency in an urban cohort of HIV-infected men under care. AIDS Patient Care STDS 2010, 24:223-227.